Pembrolizumab significantly reduced the risk of event free survival events by 30% compared with standard of care.

The Food and Drug Administration (FDA) has approved Zusduri (mitomycin intravesical solution) for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (NMIBC).

In real-world cohort, percentage weight reduction at one year was 3.6, 6.8, and 11.9% with early and late discontinuation and nondiscontinuation, respectively.

HealthDay News — For critically ill adults with sepsis, statin use is associated with reduced mortality, according to a study published online June 5 in Frontiers in Immunology.

Widaplik is indicated for the treatment of hypertension, including as initial treatment, to lower blood pressure.